Key facts
- Kervalion’s last known valuation is $4.0M (Apr 2026).
- It has raised $2.3M; the latest was Equity Crowdfunding ($2.2M) in Apr 2026.
- Notable investors include Business & Innovation Center.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Kervalion
- ·The full record, as it builds
Funding rounds
No funding rounds for Kervalion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kervalion
Developer of custom three-dimensional printed bone grafts and surgical bone substitutes designed to treat bone deficits that prevent the placement of dental implants, offering a faster and more accessible bone reconstruction system. The company offers custom-designed, ready-to-use three-dimensional printed bone substitutes with antibacterial properties, made from patient scans for perfect morphological adaptation, enabling customers to perform pre-implant dental surgery with a single surgical act, ensuring reliable bone regeneration while providing practitioners with a system that is easier, faster, and more profitable.
- Sector
- Healthcare
- HQ
- Clapiers, France
- Founded
- 2025
- Employees
- 4
- Website
- kervalion.com/
- Ownership
- Privately Held (backing)
Kervalion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kervalion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kervalion in its N-PORT filings yet. We sweep new filings monthly.